Prophylaxis Latency and Outcome in Bipolar Disorders

Canadian Journal of Psychiatry

Volumn 48, Issue 7, 2003, Pages 449-457

  Baethge, Christopher ^a,h   Tondo, Leonardo ^b,c   Bratti, Irene M ^d   Bschor, Tom ^e   Bauer, Michael ^f   Viguera, Adele C ^a,g   Baldessarini, Ross J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c L B S Inst Ctr Psychiat Res   (Italy)

^d UCLA MEDICAL CENTER   (United States)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h MCLEAN HOSPITAL   (United States)

Author keywords

Anticonvulsants; Bipolar disorder; Delayed prophylaxis; Kindling; Latency; Lithium; Major affective disorder; Outcome; Prophylaxis; Response; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; MOOD STABILIZER; UNCLASSIFIED DRUG;

BIPOLAR DISORDER; CLINICAL STUDY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HOSPITALIZATION; HUMAN; KINDLING; LATENT PERIOD; MAINTENANCE THERAPY; MAJOR AFFECTIVE DISORDER; MAJOR DEPRESSION; MEDLINE; META ANALYSIS; MORBIDITY; PROPHYLAXIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SHORT COURSE THERAPY; TREATMENT OUTCOME;

EID: 0038256006     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370304800704     Document Type: Review

References (43)

1. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998;155:30-5.
2. Baldessarini RJ, Tondo L, Hennen J, Floris G. Latency and episodes before treatment: response to lithium maintenance in bipolar I and II disorders. Bipolar Disord 1999;2:91-7.
3. Baethge C, Smolka M, Gruschka P, Berghöfer A, Schlamnann P, Bauer M, and others. Does prophylaxis-delay in BDD influence outcome? Results from a long-term study of 147 patients. Acta Psychiatr Scand 2003;107:260-7.
4. Hartong EGTM, Moleman P, Hoogduin CAL, Broekman TG, Nolen WA, the LitCar Group. Prophylactic efficacy of lithium vs carbamazepine in treatment naïve bipolar patients. J Clin Psychiatry 2003;64:144-51.
5. Post R, Weiss SRB. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992;149:999-1010.
6. Post RM, Weiss SRB. Neurobiological models of recurrence in mood disorder. In: Charney DS, Nestler EJ, Bunney BS, editors. Neurobiology of mental illness. New York: Oxford University Press; 1999. p 365-84.
7. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48:740-54.
8. Franchini L, Zanardi R, Smeraldi E, Gasperini M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999;249:227-30.
9. Seretti A, Lattuada E, Franchini L, Smeraldi E. Melancholic features and response to lithium prophylaxis in mood disorders. Depress Anxiety 2000;11:73-9.
10. Kraepelin E. Psychiatrie: Ein kurzes Lehrbuch für Studierende und Ärzte, achte, überarbeitete Auflage. Leipzig: von Barth Verlag; 1920. (Also: Barclay RM, Robertson GM, editors. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: E and S Livingstone; 1921.
11. Kraepelin E. Psychiatrie: Ein kurzes Lehrbuch für Studierende und Ärzte, achte, überarbeitete Auflage. Leipzig: von Barth Verlag; 1920. (Also: Barclay RM, Robertson GM, editors. Kraepelin E. Manic-depressive insanity and paranoia. Edinburgh: E and S Livingstone; 1921.
12. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press; 1990. p 134-6.
13. Goodwin FK, Ghaemi SN. Understanding manic-depressive illness. Arch Gen Psychiatry 1998;55:23-5.
14. Goddard GV, McIntyre DC, Leech CK. A permanent change in brain function resulting from daily electrical stimulation. Exp Neurol 1969;25:295-330.
15. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000;48:813-28.
16. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5:578-93.
17. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241-2.
18. Tondo L, Isacsson G, Baldessalini RJ. Suicide in BDD: risk and prevention. CNS Drugs 2003;17:491-511.
19. Tohen M, Zarate CA Jr, Hennen J, Kaurkhalsa H-M, Strakowski SM, Gebre-Medhin P, and others. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003. Forthcoming
20. Judd LJ, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, and others. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar disorder. Arch Gen Psychiatry 2003;60:261-9.
21. Deshauer D, Grof E, Alda M, Grof P. Patterns of DST positivity in remitted affective disorders. Biol Psychiatry 1999;45:1023-9.
22. SAS Corp. Statview-5. Cary (NC): SAS Corp; March 1998.
23. Baastrup PC, Schou M. Lithium as a prophylactic agent. Arch Gen Psychiatry 1967;16:162-72.
24. Bouman TK, Niemandsverdriet-van Kampen JG, Ormel J, Slooff C. The effectiveness of lithium in bipolar and unipolar depressions and schizoaffective disorders. J Affect Disord 1986;11:275-80.
25. Maj M, Pirozzi R, Magliano L. Late non-response to lithium pophylaxis in bipoar patients: prevalence and predictors. J Affect Disord 1996;39:39-42.
26. Kusalic M, Engelsmann. Predictors of lithium treatment responsiveness in bipolar patients. Neuropsychbiology 1998;37:146-9.
27. Kulhara P, Basu D, Mattoo SK, Sharan P, Chopra R. Lithium-prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates. J Affect Disord 1999;54:87-96.
28. Garcia-López A, Ezquiaga E, Nieves P, Rodriguez-Salvanés E. Factores predictores de requesta al litio en pacientes bipolares en seguimiento a largo plazo. Actas Esp Psiquiatr 2001;29:327-32.
29. Goldberg JF, Ernst CL. Features associated with the delayed initiation of mood stabilizers at illness onset in bipolar disorder. J Clin Psychiatry 2002;63:985-91.
30. Baldessarini RJ, Tondo L, Hennen J. Treatment latency and previous episodes: relationship to pretreatment morbidity and response to maintenance treatment in bipolar I and II disorders. Bipolar Disord 2003;5:1-11.
31. Baethge C, Gruschka P, Berghöfer A, Bauer M, Mü ller-Oerlinghausen B, Bschor T, and others. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up. J Affect Disord 2003. Forthcoming.
32. Baethge C, Gruschka P, Smolka MN, Berghöfer A, Bschor T, Müller-Oerlinghausen B, and others. Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder. J Psychiatry Neurosci 2003. Forthcoming.
33. Bratti IM, Baldessarini RJ, Baethge C, Tondo L. Pretreatment episode count and response to lithium treatment in manic-depressive illness. Harv Rev Psychiatry 2003. Forthcoming.
34. Müller-Oerlinghausen B, Berghöfer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-7.
35. Faedda GL, Baldessarini RJ, Suppes T, Tondo L, Becker I, Lipschitz D. Pediatric-onset bipolar disorder: a neglected clinical and public health problem. Harv Rev Psychiatry 1995;3:171-95.
36. Egeland JA, Blumenthal RL, Nee J, Sharpe L, Endicott J. Reliability and relationship of various age of onset criteria for major affective disorder. J Affect Diord 1987;12:159-65.
37. Post RM, Silberstein SD. Shared mechanisms in affective illness, epilepsy, and migraine. Neurology 1994;44(Suppl 7):S37-S47.
38. Slater E. Zur Periodik des manisch-depressiven Irreseins. Z Gesamte Neurol Psychiatrie 1938;162:794-801.
39. Oepen G, Salvatore P, Baldessarini RJ. On the periodicity of manic-depressive insanity by Eliot Slater (1938): translation and commentary. J Affect Disord 2003. Forthcoming.
40. Feksi AT, Kaamugisha J, Sander JWAS, Gatiti S, Shorvon SD. Comprehensive primary health care antiepileptic drug treatment program in rural and semi-urban Kenya. Lancet 1991;337:406-9.
41. Watts AE. The natural history of untreated epilepsy in a rural community in Africa. Epilepsia 1992;33:464-8.
42. Placencia M, Sander JWAS, Shorvon SD, Roman M, Alarcon F, Bimos C, and others. Antiepileptic drug treatment in a community health care setting in northern Ecuador: a prospective 12-month assessment. Epilepsy Res 1993;14:237-44.
43. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997;49:991-8.